How does abbott labs. make money?

abbott labs. generates $44.3B in annual revenue (annual revenue · their business grew +5.7% last year).

What is ABT's XVARY composite score?

abbott labs. (ABT) has an XVARY composite score of 80/100, rated above average. This combines growth, value, risk, and momentum factors.

ABT — abbott labs. stock analysis

Start here if you're new

what it is

Abbott sells medical devices, lab tests, nutrition products, and older branded drugs to hospitals, labs, and consumers worldwide.

how it gets paid

FY2025 worldwide sales were $44.3B. Medical Devices led at $21.4B (~48% of sales), per Abbott’s segment table.

why it's growing
Revenue grew 5.7% last year. Despite a soft finish in spots, Abbott still delivered respectable top- and bottom-line gains in 2025, led by medical devices while Nutrition stayed a drag.

what just happened

Abbott's latest quarter was basically a tie on EPS, with $1.50 a share matching estimates while Nutrition stayed weak.

At a glance

A+ balance sheet — rock-solid finances — built to survive anything

75/100 earnings predictability — reasonably predictable

21.1x trailing p/e — priced about right

2.5% dividend yield — cash in your pocket every quarter

19.0% return on capital — solid for a large defensive healthcare name

xvary composite: 80/100 — above average

What they do

Abbott sells medical devices, lab tests, nutrition products, and older branded drugs to hospitals, labs, and consumers worldwide.

Abbott wins by not betting on one shelf. Medical Devices are ~48% of FY2025 sales, while Diagnostics, Nutrition, and Established Pharmaceuticals make up the rest. If one aisle slows, your whole thesis does not—and Nutrition is still the segment investors watch closest after infant‑formula disruption and portfolio cleanup.

healthcare large-cap medical-devices dividend defensive

How they make money

$44.3B annual revenue · their business grew +5.7% last year

Medical Devices

$21.4B

+12.6%

Diagnostics

$8.9B

−4.3%

Nutrition

$8.5B

+0.4%

Established Pharmaceuticals

$5.5B

+6.6%

The products that matter

continuous glucose monitoring system

FreeStyle Libre

~$8B Diabetes Care FY2025 · CGM is the core growth driver

Abbott reported ~$8.0B in full‑year Diabetes Care sales in FY2025; CGM sales were $2.0B in Q4 alone (+15% reported). Libre’s replaceable sensor cadence makes this more recurring than most hardware stories.

growth engine

blood and molecular diagnostic testing

Diagnostics Portfolio

~$8.9B segment · ~20% of total revenue

This line is roughly one-fifth of company revenue on the segment table above—so even a small miss here matters when devices are doing more of the lifting.

scale matters

consumer biosensing wearable

Lingo

consumer health wearable · early-stage market

it's Abbott trying to extend a biosensor platform beyond diabetes, but this is still too early to move a $44.3B company on its own.

optionality

Key numbers

~18%

GAAP operating margin

FY2025 GAAP operating earnings were ~$8.05B on ~$44.3B sales (~18.2%)—adjusted figures are higher, but this is the clean apples‑to‑apples filing margin.

19.0%

return on capital

Return on capital → profit from each dollar invested → so what: Abbott turns investment into earnings better than most large defensive companies.

$11.6B

long-term debt

Long-term debt → money owed over years → so what: the balance sheet is still strong because that is only 6% of capital.

2.5%

dividend yield

Dividend yield → cash paid back to you each year → so what: you get paid while waiting for mid-single-digit growth.

Financial health

A+

strength

balance sheet grade A+ — near the highest rating possible
risk rank 1 — safer than 95% of stocks
price stability 95 / 100
long-term debt $11.6B (6% of capital)
net profit margin 21.7% — keeps 22 cents of every dollar in revenue
return on equity 22% — $0.22 profit for every $1 investors have put in

A+ with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.

Total return vs. market

You invested $10,000 in ABT 3 years ago → it's now worth $20,830.

The index would have given you $14,770.

same period. same starting point. ABT beat the market by $6,060.

source: institutional data · total return

What just happened

in line

Abbott's latest quarter was basically a tie on EPS, with $1.50 a share matching estimates while Nutrition stayed weak.

Q4 2025 adjusted EPS was $1.50, matching the consensus call. Full‑year 2025 adjusted EPS was $5.15 vs. $4.67 in 2024. Nutrition was the weak spot in Q4 (worldwide Nutrition sales down ~9% reported YoY in the quarter).

$11.5B

revenue (Q)

$1.50

eps (Q · adj.)

~18%

GAAP op. margin (FY)

the number that mattered

$1.50 mattered because Abbott did not miss on profit, which keeps the bull case alive while investors wait for Nutrition to stop shrinking.

abbott laboratories closed out 2025 on a somewhat disappointing note.

fourth-quarter adjusted earnings of $1.50 a share were generally in line with consensus expectations. however, total sales of $11.46 billion came up well short of the roughly $11.8 billion that wall street had been targeting on average.
much of this can be attributed to weakness in the nutrition business (sales -9% vs. prior year), where performance was hurt by lower volumes and previously announced price increases that weighed on demand, particularly within the company’s infant formula and adult nutrition product lines.
despite the soft finish to the year, abbott still delivered respectable top- and bottom-line gains in 2025, fueled primarily by continued strong momentum in the medical devices unit (sales +13% vs. prior year).
the company appears well-positioned to keep the ball rolling in 2026.
leadership is targeting adjusted earnings of $5.55-$5.80 a share this year, implying annual improvement of 10% at the midpoint.

source: company earnings report, 2026

What could go wrong

the #1 risk is FreeStyle Libre slowing before Diagnostics and Nutrition recover.

∘

med

Libre concentration risk

Diabetes Care (where Libre lives) was ~$8.0B in FY2025—roughly 37% of the $21.4B Medical Devices segment. That is a great growth engine, and it also concentrates device narrative risk in one franchise.

If Libre growth cools, a large slice of device momentum—and a visible piece of total sales—cools with it.

∘

med

Nutrition demand is wobbling

Nutrition is ~$8.5B on FY2025 reported sales (~19% of the company). Q4 worldwide Nutrition sales fell ~9% YoY as volumes and pricing actions weighed on demand.

If that weakness lasts longer than one quarter, Abbott's defensive segment stops acting defensive.

∘

med

Diagnostics still needs a cleaner reset

Diagnostics is $8.9B on FY2025 reported sales—about 20% of the company—with reported sales down ~4% year over year as COVID‑testing tailwinds fade and lab markets stay mixed.

Diagnostics plus Nutrition equal about $17.4B of revenue. If Nutrition stays choppy while Diagnostics is only slowly improving, Devices has to keep sprinting to hold group growth.

Abbott looks diversified on paper. In practice, a large Diabetes Care / Libre complex is helping mask uneven FY2025 performance across Diagnostics and Nutrition. That is manageable—it is not invisible.

source: institutional data · regulatory filings · risk analysis

Pay attention to

metric

medical devices growth staying in double digits

Devices grew 12% last year and 13% in the latest quarter. If that drops sharply, the whole mix-shift thesis gets weaker fast.

earnings

whether 2026 guidance still holds

Management guided to $5.55–$5.80 in adjusted EPS. You want the midpoint to look conservative, not ambitious.

risk

nutrition volumes after the 9% quarterly drop

Price helped, then hurt. If volumes do not stabilize, one of Abbott's steadier businesses becomes another cleanup job.

trend

diagnostics getting back to flat or better

Segment revenue here shows growth, but execution still matters—another stretch of soft testing demand or pricing pressure would push more of the story onto Libre.

Analyst rankings

short-term outlook

average

momentum score 3 — the stock is trading like the market, not ahead of it. in human-speak, nobody sees a near-term breakout here.

risk profile

safest 5%

stability score 1 — lower drawdown risk than almost any stock. this is the part of the story you pay 21x earnings for.

chart momentum

top 5%

technical score 1 — top-tier relative strength. the chart looks stronger than the debate around the fundamentals.

earnings predictability

75 / 100

management is usually reliable. you should expect steadier numbers here than in most healthcare names.

source: institutional data

Institutional activity

institutions have been net selling for 2 consecutive quarters — 1,326 buyers vs. 1,412 sellers in 3q2025. total institutional holdings: 1.4B shares. net selling for 2 quarters.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$91 $152

$109 current price

$122 target midpoint · +12% from current · 3-5yr high: $170 (+55% · 14% ann'l return)

source: institutional data · analyst targets

The deep dive

ABT

xvary deep dive

abt

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

abt

Get this snapshot in your inbox

Want the deeper analysis?